Objective: To investigate efficacy of pulmonary surfactant in the treatment of Adult Respiratory Distress Syndrome (ARDS).
Methods: From April 21, 2016 to April 21, 2017 100 cases of adult respiratory distress syndrome treated in our hospital were divided into the observation group and the control group with 50 cases in each. Patients in the control group were treated with conventional mechanical ventilation while those in the observation group were given pulmonary surfactant.
Results: Compared with the control group, the observation group has better performance in terms of PaO2/FiO2 (115.68 ± 13.48), PaCO2 (40.63 ± 11.58), PaO2 (64.23 ± 5.69), time span of oxygenation (102.48 ± 12.69 h), high concentration oxygen duration (3.45 ± 0.22 h), mechanical ventilation time (82.36 ± 3.47 h), total incidence of complications (2%) and total effective rate (98%) of statistical significance, (P<0.05).
Conclusion: Pulmonary surfactant is effective and safe in the treatment of adult respiratory distress syndrome.